Pfizer Price to Sales Ratio 2012-2026 | PFE
Historical PS ratio values for Pfizer (PFE) over the last 10 years. The current P/S ratio for Pfizer as of June 08, 2026 is .
| Pfizer P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-06-09 | 25.70 | 2.32 | |
| 2026-03-31 | 27.62 | $11.09 | 2.49 |
| 2025-12-31 | 24.09 | $10.97 | 2.20 |
| 2025-09-30 | 24.23 | $11.00 | 2.20 |
| 2025-06-30 | 22.66 | $11.19 | 2.02 |
| 2025-03-31 | 23.24 | $10.95 | 2.12 |
| 2024-12-31 | 23.94 | $11.16 | 2.14 |
| 2024-09-30 | 25.71 | $10.60 | 2.43 |
| 2024-06-30 | 24.51 | $9.89 | 2.48 |
| 2024-03-31 | 23.95 | $9.83 | 2.44 |
| 2023-12-31 | 24.48 | $10.45 | 2.34 |
| 2023-09-30 | 27.83 | $12.28 | 2.27 |
| 2023-06-30 | 30.43 | $13.85 | 2.20 |
| 2023-03-31 | 33.49 | $16.43 | 2.04 |
| 2022-12-31 | 41.68 | $17.66 | 2.36 |
| 2022-09-30 | 35.29 | $17.45 | 2.02 |
| 2022-06-30 | 41.96 | $17.69 | 2.37 |
| 2022-03-31 | 41.09 | $16.16 | 2.54 |
| 2021-12-31 | 46.52 | $14.27 | 3.26 |
| 2021-09-30 | 33.59 | $12.12 | 2.77 |
| 2021-06-30 | 30.31 | $9.75 | 3.11 |
| 2021-03-31 | 27.77 | $8.17 | 3.40 |
| 2020-12-31 | 27.91 | $7.41 | 3.77 |
| 2020-09-30 | 26.13 | $5.70 | 4.58 |
| 2020-06-30 | 23.06 | $6.12 | 3.77 |
| 2020-03-31 | 22.79 | $6.70 | 3.40 |
| 2019-12-31 | 27.08 | $7.19 | 3.77 |
| 2019-09-30 | 24.59 | $7.06 | 3.48 |
| 2019-06-30 | 29.38 | $7.03 | 4.18 |
| 2019-03-31 | 28.55 | $6.96 | 4.10 |
| 2018-12-31 | 29.09 | $6.81 | 4.27 |
| 2018-09-30 | 29.14 | $8.88 | 3.28 |
| 2018-06-30 | 23.79 | $8.83 | 2.69 |
| 2018-03-31 | 23.04 | $8.71 | 2.65 |
| 2017-12-31 | 23.30 | $8.68 | 2.69 |
| 2017-09-30 | 22.76 | $8.63 | 2.64 |
| 2017-06-30 | 21.21 | $8.57 | 2.48 |
| 2017-03-31 | 21.39 | $8.57 | 2.50 |
| 2016-12-31 | 20.10 | $8.56 | 2.35 |
| 2016-09-30 | 20.76 | $8.59 | 2.42 |
| 2016-06-30 | 21.40 | $8.41 | 2.55 |
| 2016-03-31 | 17.86 | $8.17 | 2.19 |
| 2015-12-31 | 19.25 | $7.81 | 2.47 |
| 2015-09-30 | 18.58 | $7.60 | 2.44 |
| 2015-06-30 | 19.68 | $7.60 | 2.59 |
| 2015-03-31 | 20.26 | $7.68 | 2.64 |
| 2014-12-31 | 17.98 | $7.71 | 2.33 |
| 2014-09-30 | 16.92 | $7.63 | 2.22 |
| 2014-06-30 | 16.83 | $7.60 | 2.21 |
| 2014-03-31 | 18.06 | $7.44 | 2.43 |
| 2013-12-31 | 17.08 | $7.40 | 2.31 |
| 2013-09-30 | 15.90 | $7.14 | 2.23 |
| 2013-06-30 | 15.37 | $6.97 | 2.21 |
| 2013-03-31 | 15.71 | $7.00 | 2.24 |
| 2012-12-31 | 13.53 | $7.25 | 1.87 |
| 2012-09-30 | 13.29 | $6.99 | 1.90 |
| 2012-06-30 | 12.19 | $7.39 | 1.65 |
| 2012-03-31 | 11.88 | $7.62 | 1.56 |
| 2011-12-31 | 11.24 | $7.71 | 1.46 |
| 2011-09-30 | 9.09 | $8.17 | 1.11 |
| 2011-06-30 | 10.47 | $8.03 | 1.30 |
| 2011-03-31 | 10.23 | $8.08 | 1.27 |
| 2010-12-31 | 8.73 | $8.07 | 1.08 |
| 2010-09-30 | 8.47 | $8.40 | 1.01 |
| 2010-06-30 | 6.96 | $8.13 | 0.86 |
| 2010-03-31 | 8.28 | $7.63 | 1.08 |
| 2009-12-31 | 8.70 | $7.20 | 1.21 |
| 2009-09-30 | 7.84 | $6.78 | 1.16 |
| 2009-06-30 | 7.03 | $6.84 | 1.03 |
| 2009-03-31 | 6.32 | $7.01 | 0.90 |
| 2008-12-31 | 8.04 | $7.16 | 1.12 |
| 2008-09-30 | 8.22 | $7.18 | 1.15 |
| 2008-06-30 | 7.67 | $7.14 | 1.07 |
| 2008-03-31 | 9.04 | $6.93 | 1.30 |
| 2007-12-31 | 9.68 | $6.94 | 1.39 |
| 2007-09-30 | 10.28 | $6.82 | 1.51 |
| 2007-06-30 | 10.63 | $6.77 | 1.57 |
| 2007-03-31 | 10.39 | $6.80 | 1.53 |
| 2006-12-31 | 10.54 | $6.63 | 1.59 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |